Login to Your Account

Regulatory NEWS

The hearing at the U.S. Patent and Trademark Office regarding two patents for CRISPR is a pivotal moment for the IP associated with the technology, but Bob Underwood, a partner at the Chicago office of McDermott Will & Emery, said that prognostication on the outcome is a dicey exercise.

Even as they reached across the aisle to pat each other on the back in the lead-up to Wednesday's 392-26 House vote on the 21st Century Cures Act, several lawmakers signaled that the $6.3 billion bipartisan package is just the beginning of congressional action to increase funding for medical research.

In a week dotted with big news for the life science industries, the passage of 21st Century Cures legislation in the House of Representatives is perhaps the biggest. Investors and industry are understandably enthused at the development.

More Regulatory Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: